416 related articles for article (PubMed ID: 21999133)
21. Autologous dendritic cell vaccines for non-small-cell lung cancer.
Hirschowitz EA; Foody T; Kryscio R; Dickson L; Sturgill J; Yannelli J
J Clin Oncol; 2004 Jul; 22(14):2808-15. PubMed ID: 15254048
[TBL] [Abstract][Full Text] [Related]
22. Novel targeted agents for lung cancer.
West HJ
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant immunotherapy for non-small cell lung cancer.
Tucker ZC; Laguna BA; Moon E; Singhal S
Cancer Treat Rev; 2012 Oct; 38(6):650-61. PubMed ID: 22226940
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
Ruiz R; Hunis B; Raez LE
Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
[TBL] [Abstract][Full Text] [Related]
25. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
26. Non-small-cell lung carcinoma vaccines in clinical trials.
Rossi A; Maione P; Schettino C; Bareschino MA; Sacco PC; Ambrosio R; Barbato V; Zeppa R; Palazzolo G; Gridelli C
Expert Rev Vaccines; 2011 Jun; 10(6):887-97. PubMed ID: 21692707
[TBL] [Abstract][Full Text] [Related]
27. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
Tyagi P; Mirakhur B
Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
[TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
30. Current immunotherapeutic strategies in lung cancer.
Rüttinger D; Hatz RA; Jauch KW; Fox BA
Surg Oncol Clin N Am; 2007 Oct; 16(4):901-18, x. PubMed ID: 18022551
[TBL] [Abstract][Full Text] [Related]
31. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
[TBL] [Abstract][Full Text] [Related]
32. The role of targeted therapy in non-small cell lung cancer.
Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
[TBL] [Abstract][Full Text] [Related]
33. Are vaccines making a comeback in non-small-cell lung cancer?
Nemunaitis JJ
J Clin Oncol; 2008 Mar; 26(9):1402-3. PubMed ID: 18349390
[No Abstract] [Full Text] [Related]
34. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.
Decoster L; Wauters I; Vansteenkiste JF
Ann Oncol; 2012 Jun; 23(6):1387-93. PubMed ID: 22156658
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for lung cancer.
Bradbury PA; Shepherd FA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S164-70. PubMed ID: 18520304
[TBL] [Abstract][Full Text] [Related]
36. Technology evaluation: BLP-25, Biomira Inc.
Morse MA
Curr Opin Mol Ther; 2001 Feb; 3(1):102-5. PubMed ID: 11249725
[TBL] [Abstract][Full Text] [Related]
37. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
[TBL] [Abstract][Full Text] [Related]
38. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Wang S; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
[TBL] [Abstract][Full Text] [Related]
39. Vaccines and immunotherapy for non-small cell lung cancer.
Morgensztern D; Goodgame B; Govindan R
J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S463-5. PubMed ID: 21102240
[No Abstract] [Full Text] [Related]
40. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
Hall RD; Gray JE; Chiappori AA
Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
